Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124620363 | 12462036 | 3 | F | 20160301 | 20160707 | 20160613 | 20160713 | EXP | CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2016-BI-20943II | BOEHRINGER INGELHEIM | 56.00 | YR | F | Y | 75.00000 | KG | 20160713 | MD | COUNTRY NOT SPECIFIED | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124620363 | 12462036 | 1 | PS | DABIGATRAN | DABIGATRAN | 1 | Oral | 220 MG | B141000158 | 22512 | 110 | MG | CAPSULE | BID | |||||
| 124620363 | 12462036 | 2 | SS | ARIMIDEX | ANASTROZOLE | 1 | Unknown | U | 0 | ||||||||||
| 124620363 | 12462036 | 3 | C | ENALAPRIL | ENALAPRIL | 1 | Oral | 10 MG | 0 | 5 | MG | BID | |||||||
| 124620363 | 12462036 | 4 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 0 | BID | ||||||||||
| 124620363 | 12462036 | 5 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MG | 0 | 20 | MG | QD | |||||||
| 124620363 | 12462036 | 6 | C | ANASTROZOLE. | ANASTROZOLE | 1 | Oral | 1 MG | 0 | 1 | MG | QD | |||||||
| 124620363 | 12462036 | 7 | C | AMLODIPIN | AMLODIPINE BESYLATE | 1 | Oral | 10 MG | 0 | 10 | MG | QD | |||||||
| 124620363 | 12462036 | 8 | C | MORPHINE | MORPHINE | 1 | Subcutaneous | 20 MG/5ML | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124620363 | 12462036 | 1 | Post procedural myocardial infarction |
| 124620363 | 12462036 | 2 | Product used for unknown indication |
| 124620363 | 12462036 | 3 | Product used for unknown indication |
| 124620363 | 12462036 | 4 | Product used for unknown indication |
| 124620363 | 12462036 | 5 | Post procedural myocardial infarction |
| 124620363 | 12462036 | 6 | Product used for unknown indication |
| 124620363 | 12462036 | 7 | Product used for unknown indication |
| 124620363 | 12462036 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124620363 | 12462036 | HO |
| 124620363 | 12462036 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124620363 | 12462036 | Drug hypersensitivity | |
| 124620363 | 12462036 | Drug-induced liver injury | |
| 124620363 | 12462036 | Hepatotoxicity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124620363 | 12462036 | 1 | 20151217 | 20160304 | 0 | |
| 124620363 | 12462036 | 3 | 20160310 | 0 | ||
| 124620363 | 12462036 | 4 | 20160310 | 0 | ||
| 124620363 | 12462036 | 5 | 20150312 | 20160307 | 0 | |
| 124620363 | 12462036 | 6 | 20160310 | 0 | ||
| 124620363 | 12462036 | 7 | 20160310 | 0 | ||
| 124620363 | 12462036 | 8 | 20160319 | 0 |